IN THE CLAIMS:

Please amend the claims as follows:

- 1-7. (Canceled)
- 8. (Currently Amended) [[An]] <u>A human</u> anti-<u>human</u> CD40 antibody or a functional fragment thereof, wherein the antibody or a functional fragment thereof inhibits tonsillar B cell proliferation in vitro, wherein the inhibitory efficiency leads to about 50 to 95% or greater reduction in B cell proliferation when the concentration of the antibody is in the range of 0.01 μg/ml to 10 μg/ml_and in the presence of a mixture of human flag-tagged CD40L at 1 ug/ml and CD40L enhancer antibody (Alexis) at 1 ug/ml.
- 9. (Currently Amended) [[An]] <u>A human</u> anti-<u>human</u> CD40 antibody or a functional fragment thereof, wherein the antibody or a functional fragment thereof inhibits tonsillar B cell proliferation in vitro, wherein the inhibitory efficiency leads to about a 85 to 95% or greater reduction in B cell proliferation when the concentration of the antibody is in the range of 0.1 μg/ml to 10 μg/ml and in the presence of a mixture of human flag-tagged CD40L at 1 ug/ml and CD40L enhancer antibody (<u>Alexis</u>) at 1 ug/ml.
- 10. (Currently Amended) [[An]] <u>A human</u> anti-<u>human</u> CD40 antibody or a functional fragment thereof, wherein the antibody or a functional fragment thereof inhibits tonsillar B cell proliferation in vitro, wherein the inhibitory efficiency leads to about 80 to 95% or greater reduction in B cell proliferation when the concentration of the antibody is in the range of 0.01 μg/ml to 10 μg/ml and in the presence of a mixture of human flag-tagged CD40L at 1 ug/ml and CD40L enhancer antibody (Alexis) at 1 ug/ml.
- 11. (Currently Amended) [[An]] <u>A human</u> anti-<u>human</u> CD40 antibody or a functional fragment thereof, wherein the antibody or a functional fragment thereof inhibits tonsillar B cell proliferation in vitro, wherein the inhibitory efficiency leads to about a 95% or greater reduction in B cell proliferation when the concentration of the antibody is in the range of 0.1 μg/ml to 10 μg/ml_and in the presence of a mixture of human flag-tagged CD40L at 1 ug/ml and CD40L enhancer antibody (<u>Alexis</u>) at 1 ug/ml.

12. -19 (Canceled)

- 20. (Currently Amended) The <u>human</u> anti-<u>human</u> CD40 antibody or a functional fragment thereof of claims 8 through 11 wherein the heavy chain variable region and the light chain variable region of the antibody are the product of a human-derived antibody gene.
- 21. (Currently Amended) A pharmaceutical composition comprising at least one <u>human</u> anti-<u>human</u> CD40 antibody or a functional fragment thereof selected from claims 8 through 11 and 20.
- 22. (Withdrawn) An isolated DNA molecule encoding the heavy chain variable amino acid sequence of SEQ ID 16.
- 23. (Withdrawn) The isolated DNA molecule of claim 16, wherein the DNA sequence comprises SEQ ID 14.
- 24. (Withdrawn) An isolated DNA molecule encoding the light chain variable amino acid sequence of SEQ ID 17.
- 25. (Withdrawn) The isolated DNA molecule of claim 16, wherein the DNA sequence comprises SEQ ID 15.
- 26. (Withdrawn) An isolated DNA molecule encoding the heavy chain variable amino acid sequence of the antibody produced by the hybridoma F1-102, F5-77, F5-152, F2-103, F5-157, 72, or F4-465.
- 27. (Withdrawn) An isolated DNA molecule encoding the light chain variable amino acid sequence of the antibody produced by the hybridoma F1-102, F5-77, F5-152, F2-103, F5-157, 72, or F4-465.
- 28. (Withdrawn) An isolated DNA molecule wherein the DNA sequence comprises SEQ ID 10, SEQ ID 11, SEQ ID 12, SEQ ID 13, SEQ ID 14 or SEQ ID 15.
- 29. (Canceled)

- 30. (Withdrawn) A host cell containing the nucleic acid selected from claims 22 through 28.
- 31. (Canceled)